Tango Net Receivables from 2010 to 2024
| TNGX Stock | USD 3.94 0.14 3.43% |
Net Receivables | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 703.7 K |
Check Tango Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tango Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 M, Interest Expense of 3.6 M or Selling General Administrative of 22.1 M, as well as many indicators such as Price To Sales Ratio of 19.37, Dividend Yield of 0.0 or PTB Ratio of 6.45. Tango financial statements analysis is a perfect complement when working with Tango Therapeutics Valuation or Volatility modules.
Tango | Net Receivables |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.